Literature DB >> 32379875

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P Kater1, J Joseph Melenhorst2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32379875     DOI： 10.1182/blood.2020005362

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR.

Authors:  Biqin Tan; Rong Dong; Bo Zhang; Youyou Yan; Qingyu Li; Fei Wang; Nengming Lin
Journal:  Cancer Cell Int       Date:  2020-09-17       Impact factor: 5.722

Review 2.  Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.

Authors:  Gabrielle Leclercq; Nathalie Steinhoff; Hélène Haegel; Donata De Marco; Marina Bacac; Christian Klein
Journal:  Oncoimmunology       Date:  2022-06-01       Impact factor: 7.723

Review 3.  Engineering enhanced CAR T-cells for improved cancer therapy.

Authors:  Michael C Milone; Jie Xu; Sai-Juan Chen; McKensie A Collins; Jianfeng Zhou; Daniel J Powell; J Joseph Melenhorst
Journal:  Nat Cancer       Date:  2021-08-19

Review 4.  Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Authors:  Yanyan Liu; Yongping Song; Qingsong Yin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.